XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.21.1

Statements of Operations-Additional Information | 9 Months Ended
--- | ---
Mar. 31, 2021
Statements of Operations-Additional Information |
Statements of Operations-Additional Information | 3. Statements of Operations—Additional Information Disaggregated revenue, deferred revenue and customer payment terms We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle, and aquaculture. The products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition. The animal health and mineral nutrition products are sold directly to integrated poultry, swine and cattle integrators and through commercial animal feed manufacturers, wholesalers and distributors. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused in regions where the majority of livestock production is consolidated in large commercial farms. We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team. Animal Health The Animal Health business develops, manufactures and markets products in three main categories:
| ● | MFAs and Other: MFAs and other products primarily consist of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products.
| ● | Nutritional Specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health.
| ● | Vaccines: Our vaccines are primarily focused on preventing diseases in poultry and swine. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products and produce and market adjuvants to vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.
Mineral Nutrition The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine and beef and dairy cattle. Performance Products The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States. The following tables present our revenues disaggregated by major product category and geographic region: Net Sales by Product Type ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2021 |  | 2020 |  | 2021 |  | 2020
Animal Health |  | ​ |  |  | ​ |  | ​ | ​ |  |  | ​ |
MFAs and other | ​ | $ | 78,530 | ​ | $ | 82,670 | ​ | $ | 238,810 | ​ | $ | 249,659
Nutritional specialties | ​ |  | 36,978 | ​ |  | 34,636 | ​ |  | 105,972 | ​ |  | 98,131
Vaccines | ​ |  | 18,872 | ​ |  | 21,668 | ​ |  | 54,205 | ​ |  | 56,723
Total Animal Health | ​ | $ | 134,380 | ​ | $ | 138,974 | ​ | $ | 398,987 | ​ | $ | 404,513
Mineral Nutrition | ​ |  | 58,153 | ​ |  | 56,200 | ​ |  | 163,750 | ​ |  | 164,534
Performance Products | ​ |  | 19,196 | ​ |  | 15,565 | ​ |  | 50,335 | ​ |  | 45,424
Total | ​ | $ | 211,729 | ​ | $ | 210,739 | ​ | $ | 613,072 | ​ | $ | 614,471
​ Net Sales by Region ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2021 |  | 2020 |  | 2021 |  | 2020
United States | ​ | $ | 129,370 | ​ | $ | 126,826 | ​ | $ | 370,446 | ​ | $ | 368,230
Latin America and Canada | ​ |  | 37,386 | ​ |  | 40,284 | ​ |  | 115,808 | ​ |  | 119,730
Europe, Middle East and Africa | ​ |  | 27,802 | ​ |  | 31,958 | ​ |  | 84,959 | ​ |  | 83,311
Asia Pacific | ​ |  | 17,171 | ​ |  | 11,670 | ​ |  | 41,859 | ​ |  | 43,200
Total | ​ | $ | 211,729 | ​ | $ | 210,739 | ​ | $ | 613,072 | ​ | $ | 614,471
​ Net sales by region are based on country of destination. Deferred revenue was $3,815 and $4,570 as of March 31, 2021, and June 30, 2020, respectively. Accrued expenses and other current liabilities included $1,325 and $1,109 of the total deferred revenue as of March 31, 2021, and June 30, 2020, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand-alone sales prices of the individual products or services. Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized. Interest Expense and Depreciation and Amortization ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2021 |  | 2020 |  | 2021 |  | 2020
Interest expense, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Term loan | ​ | $ | 1,857 | ​ | $ | 1,888 | ​ | $ | 5,796 | ​ | $ | 5,967
Revolving credit facility | ​ |  | 938 | ​ |  | 1,400 | ​ |  | 3,017 | ​ |  | 4,361
Amortization of debt issuance costs | ​ |  | 221 | ​ |  | 220 | ​ |  | 662 | ​ |  | 662
Other | ​ |  | 65 | ​ |  | 153 | ​ |  | 191 | ​ |  | 441
Interest expense | ​ |  | 3,081 | ​ |  | 3,661 | ​ |  | 9,666 | ​ |  | 11,431
Interest income | ​ |  | (148) | ​ |  | (398) | ​ |  | (709) | ​ |  | (1,382)
​ | ​ | $ | 2,933 | ​ | $ | 3,263 | ​ | $ | 8,957 | ​ | $ | 10,049
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2021 |  | 2020 |  | 2021 |  | 2020
Depreciation and amortization | ​ |  | ​ | ​ |  |  | ​ |  | ​ | ​ |  |
Depreciation of property, plant and equipment | ​ | $ | 5,763 | ​ | $ | 5,824 | ​ | $ | 17,479 | ​ | $ | 17,395
Amortization of intangible assets | ​ |  | 2,155 | ​ |  | 2,325 | ​ |  | 6,563 | ​ |  | 6,659
Amortization of other assets | ​ |  | — | ​ |  | 99 | ​ |  | — | ​ |  | 123
​ | ​ | $ | 7,918 | ​ | $ | 8,248 | ​ | $ | 24,042 | ​ | $ | 24,177
​

X
- References No definition available. + Details
Name: | pahc_StatementsOfOperationsAdditionalInformationAbstract
Namespace Prefix: | pahc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration